Despite being the commonest severe inherited disorder affecting millions of people worldwide, treatment for SCD remains problematical. As complications of SCD follow from polymerisation of HbS and RBC sickling, there has been considerable effort directed at discovering novel anti-sickling reagents.Many of these have been designed to interact directly with HbS, to stabilise the oxy conformation (increasing O2 affinity) and to inhibit polymerisation